IgG4-Related Diseases
8
6
6
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (8)
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis
A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases
A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
AYLo - AutoimmunitY and Loss of y
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Key Mechanisms of Abnormal T Cell Activation and Differentiation in IgG4-Related Ophthalmic Disease